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Abstract
Background: The Medical Research Council (MRC) ORACLE trial evaluated the use of co-amoxiclav 375
mg and/or erythromycin 250 mg in women presenting with preterm rupture of membranes (PROM)
ORACLE I or in spontaneous preterm labour (SPL) ORACLE II using a factorial design. The results showed
that for women with a singleton baby with PROM the prescription of erythromycin is associated with
improvements in short term neonatal outcomes, although co-amoxiclav is associated with prolongation of
pregnancy, a significantly higher rate of neonatal necrotising enterocolitis was found in these babies.
Prescription of erythromycin is now established practice for women with PROM. For women with SPL
antibiotics demonstrated no improvements in short term neonatal outcomes and are not recommended
treatment. There is evidence that both these conditions are associated with subclinical infection so
perinatal antibiotic administration may reduce the risk of later disabilities, including cerebral palsy, although
the risk may be increased through exposure to inflammatory cytokines, so assessment of longer term
functional and educational outcomes is appropriate.
Methods: The MRC ORACLE Children's Study will follow up UK children at age 7 years born to 4809
women with PROM and the 4266 women with SPL enrolled in the earlier ORACLE trials. We will use a
parental questionnaire including validated tools to assess disability and behaviour. We will collect the
frequency of specific medical conditions: cerebral palsy, epilepsy, respiratory illness including asthma,
diabetes, admission to hospital in last year and other diseases, as reported by parents.
National standard test results will be collected to assess educational attainment at Key Stage 1 for children
in England.
Discussion: This study is designed to investigate whether or not peripartum antibiotics improve health
and disability for children at 7 years of age.
Trial registration: The ORACLE Trial and Children Study is registered in the Current Controlled Trials
registry. ISCRTN 52995660
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Background & Rationale
The sequaelae of preterm birth pose a significant public
health problem. Children born before 37 weeks gesta-
tional age are at increasing risk of major disabilities, such
as cerebral palsy, with decreasing gestation [1]. Further-
more, of the preterm children without disability, many
will have important behavioural and educational difficul-
ties. The ORACLE Children Study presents a unique
opportunity to determine if a simple, inexpensive inter-
vention reduces the long term sequaelae of preterm birth
with benefit for individuals and their families.
The ORACLE trial evaluated the prescription of Co-amox-
iclav 375 mg and/or erythromycin 250 mg to women
either with PROM [2] or in SPL [3]. The trial reported that
erythromycin did improve the composite primary out-
come (death or major cerebral abnormality on ultrasound
prior to discharge or chronic lung disease defined as need-
ing oxygen therapy at 36/40 post conceptual age) in sin-
gleton babies born to women after PROM. The
prescription of Erythromycin was also associated with
improvement in other significant outcomes such as pro-
longation of pregnancy, reduction in the need for neona-
tal ventilation, oxygenation and treatment with
surfactant, a decrease in oxygen dependence at 28 days of
age or older, and fewer positive neonatal blood cultures.
Although Co-amoxiclav was associated with prolongation
of pregnancy, a significantly higher incidence of neonatal
necrotising enterocolitis was found in these babies. In the
group of women with SPL the use of neither Co-amoxiclav
nor erythromycin were associated with any improvement
in neonatal morbidity or mortality.
Following the ORACLE trial antibiotic treatment for pre-
term, prelabour rupture of the membranes (PROM) may
become standard practice and so there will never be
another opportunity to undertake this study and provide
unbiased and reliable evidence on this subject.
There is increasing evidence that, in addition to preterm
birth, perinatal infection is an independent antecedent of
other disability, particularly cerebral palsy and chronic
lung disease. Therefore, perinatal administration of anti-
biotics could prevent neurological and respiratory disabil-
ity by two mechanisms, either by prolonging pregnancy
and/or by eliminating infection. In contrast however, it is
possible that prolongation of pregnancy may increase
rather than decrease the risk of disability by continuing
fetal exposure to inflammatory cytokines, which have also
been implicated in the genesis of neurological damage [4]
and chronic lung disease [5]. Some clinical evidence to
support this possibility comes from two observational
studies of neurodevelopmental outcome in preterm
infants born after PROM which showed a higher risk of
cerebral palsy or neurological impairment compared with
gestation matched controls [6,7]. In addition, duration of
membrane rupture had a direct relationship with the risk
of neurological impairment [7].
The cerebral and respiratory benefits reported with eryth-
romycin in women with PROM in the ORACLE trial may
have been secondary to (a) prolongation of pregnancy
and (b) a reduction of the effects of fetal and neonatal
lung infection or inflammation. Supportive evidence for
the latter comes from broncho-alveolar lavage fluid stud-
ies. Studies of the constituents of broncho alveolar lavage
fluid have shown that infants who develop chronic lung
disease have higher concentrations of neutrophils [8],
proinflammatory cytokines[9,10] and proxy markers of
neutrophil recruitment, than those who recover from res-
piratory distress syndrome[9,11]. There is also evidence
that intrauterine lung inflammation is implicated in the
genesis of chronic lung disease, since high concentrations
of the potent profibrotic agent, transforming growth fac-
tor, have been described in the first broncho-alveolar lav-
age fluid after birth of infants who go on to develop
chronic lung disease [5,12]. The MRC ORACLE Children
Study provides a unique opportunity to determine
whether the reductions in chronic lung disease found at
discharge from hospital in the erythromycin group are
reflected in a decreased incidence of respiratory disease
and the need for therapy at 7 years of age.
Follow-up of the infants of women who presented with
SPL is important, even in the absence of an apparent effect
of antibiotics from ORACLE II [3] on short term morbid-
ity. Many clinicians and researchers are convinced from
observational evidence that a substantial proportion of
SPL is caused by sub-clinical infection [13]. If this evi-
dence is indeed correct then differences in childhood neu-
rodevelopment and respiratory function could be
detected between children born to women randomised to
antibiotics compared with those randomised to placebo
even though crude measures of early neurological damage
or respiratory disease were no different between the
groups during the perinatal period.
Methods/Design
ORACLE was a double blind randomised controlled facto-
rial design trial which evaluated whether giving broad
spectrum antibiotics to women in SPL or with PROM
improved neonatal mortality and morbidity.
Women were randomised to receive antibiotics and
matching placebos 4 times daily for 10 days or until deliv-
ery, whichever was sooner. ORACLE tested Co-amoxiclav
375 mg and erythromycin 250 mg singularly and in com-
bination.BMC Pregnancy and Childbirth 2008, 8:14 http://www.biomedcentral.com/1471-2393/8/14
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This phase of the study – the MRC ORACLE Children
Study – will follow-up children of women randomised to
ORACLE at 7 years of age to determine whether antibiot-
ics have effects on their development, educational attain-
ment, and the risk of conditions such as cerebral palsy and
respiratory illness. The MRC ORACLE Children Study will
include the 8942 children born to those women ran-
domised in the UK.
Primary & secondary outcomes
The primary outcome is:
1) the overall level of disability (severe, moderate, mild,
none) derived from the Multi-Attribute Health Status
(MAHS) classification system.
The secondary outcomes are:
1) number of children with 3 or more abnormal attributes
derived from the MAHS classification system
2) degree of function (severe, moderate, mild, none)
within the 9 domains of vision, hearing, speech, ambula-
tion, dexterity, emotions, cognition, pain and self care.
3) behaviour (Goodman's strengths and difficulties ques-
tionnaire).
4) educational achievement in reading, mathematics and
writing at Key Stage 1. Data on both levels and raw scores
will be collected.
5) incidence of specific medical conditions:
• cerebral palsy
• epilepsy
• respiratory illness including asthma
• diabetes
• admission to hospital in last year
• other diseases
• death – from trial entry to aged 7 years
- from initial discharge from hospital to aged 7 years
• covariates – family demographic information (housing
status, ethnic group, smoking practice) will be collected.
Inclusion/exclusion criteria
Inclusions
• surviving children of mothers recruited to the ORACLE
trial
• child resident in UK
Exclusions
• recruited outside UK
• adopted or fostered children and children who have
emigrated
Children who have been adopted or fostered will not be
followed-up to avoid potential distress to parents and
child. Children born in Scotland, Northern Ireland or
Wales have different National Tests to England and there-
fore will not have data collected to assess educational
achievement.
Postal parent-report questionnaire
A parental questionnaire will be administered to deter-
mine the level of disability (severe, moderate, mild,
none). This is based on the Multi-Attribute Health Status
(MAHS) Mark II and III [14] classification system devel-
oped and widely tested by the Departments of Paediatrics
and Clinical Epidemiology and Biostatistics of McMaster
University, Canada. The additional domain of behaviour
is being assessed using the strengths and difficulties ques-
tionnaire developed and validated by Robert Goodman
[15]. Additional questions will assess the other health
related outcomes. Deaths will be categorised hierarchi-
cally using the system below developed by PMG and with
the advice of Steve Gould, Consultant Pathologist, John
Radcliffe Hospital, Oxford
Death categorisations
1. Congenital abnormality
2. Cancer/Neoplasia
3. Complications of Prematurity
3a. Chronic lung disease
3b. CLD and CNS
3c. Central Nervous System related to prematurity
4. Central Nervous System
5. Infection
6. MiscellaneousBMC Pregnancy and Childbirth 2008, 8:14 http://www.biomedcentral.com/1471-2393/8/14
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7. Sudden Unexpected Death in Infancy (SUDIs, SIDS and
Unascertained)
National Tests
In England we will employ a unique and innovative
approach of using the standard National Tests (Key Stage
1) to assess the children's educational ability supported by
the Qualifications and Curriculum Authority (QCA). Dfes
will provide anonymised data for test level achieved and
ethnicity of all children in each treatment group. For those
children for whom parental consent is obtained level data
will be obtained from the Local Education Authority
(LEA) and the scores for each question will be collected
from individual schools. Children in Northern Ireland
and Wales have different National Tests and no such tests
are conducted in Scotland therefore these children will
not have data collected to assess educational achievement.
Estimated power of study
A total of 8942 babies survived until the end of data col-
lection in England, Scotland, Wales and Northern Ireland.
Of these, 4521 were in the SPL group and 4421 were in the
PROM group. Not all of these babies will have survived
until age 7 years; assuming an 85% response rate to a
parental questionnaire, 3843 responses can be expected
from the SPL group and 3758 from the PROM group
(7601 in total).
Table 1 demonstrates the differences detectable between
any two intervention groups for the listed primary meas-
ure (e.g. erythromycin vs. erythromycin-placebo) in each
of the specified sub-groups (SPL and PROM). The esti-
mates of prevalence of disability are based on data derived
using the same instrument (MAHS Mark II) [14] on
extremely low birth weight (ELBW) babies compared with
a reference group of normal birth weight babies. As the
majority of ELBW babies are born less than 28 weeks ges-
tation they will have a higher prevalence of disability than
the children included in the MRC ORACLE Children
Study. For the measure of '3 or more attributes' affected,
an incidence of 28% occurred in the ELBW group com-
pared with 2% in the reference group. As the gestational
age of the ORACLE population of children is between
these extremes a conservative disability estimate of 5%
has been taken as the principal estimate and sensitivity to
variation of this value of the power of the study to detect
differences is explored in the table. By ranking children
into groups by their degree of disability (the number of
attributes affected) the power of the study to demonstrate
smaller differences will be increased by using tests for
trends.
Analyses plan
The primary analysis will comprise comparison of MAHS
disability prevalence by allocated treatment group,
through fitting of logistic models including terms indicat-
ing allocation to Co-amoxiclav/not and to Erythromycin/
not, together with an interaction term. Both HUI2 and
HUI3 data will be collected and analysed as they have
been designed to complement one another but are based
on the same conceptual framework. HUI2 refers to worry
and anxiety, HUI3 to happiness versus depression. Simi-
larly while both refer to the degree of severity of pain,
HUI2 focuses on the use of analgesia while HUI3 focuses
on the disruption of activities. Self-care is only available in
HUI2 and dexterity only in HUI3. Sensitivity analyses will
include i) logistic modelling of the MAHS level of disabil-
ity, ii) corresponding models for risk differences, iii) alter-
native approaches to analysing outcomes from multiple
births, and iv) models adjusted for demographic covari-
ates if their balance deteriorates during further follow up,
and for other covariates including length of gestation, and
year of KS1 assessment and original ORACLE outcomes.
Analyses of secondary outcomes will follow the approach
for the primary outcome, appropriately modified where
necessary to accommodate continuous or survival meas-
ures. Details of the analysis of KS1 data are to be devel-
oped in collaboration with colleagues in the agency
responsible for collection and interpretation of these data.
Explicit allowance for multiplicity of comparisons will be
made in interpretation of the results.
Planned subgroup analyses
Comparisons of primary and secondary outcomes will be
undertaken for the infants of women with: (1) SPL –
intact membranes; (2) PROM; (3) multiple & singleton
pregnancies; (4) >32 week gestation and < 32 week gesta-
tion; (5) > < 28 weeks gestation.
Table 1: For each sub-group (PROM or SPL), a response from 3700 babies will allow the following differences to be detected with 80% 
power:
Outcome Incidence in erythromycin group Incidence in erythromycin placebo group Relative risk reduction
'3 or more attributes affected' 3.1% 5% 38%
5.6% 8% 30%
1.5% 3% 50%BMC Pregnancy and Childbirth 2008, 8:14 http://www.biomedcentral.com/1471-2393/8/14
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Data collection
The women were aware of the possibility of a Follow-Up
Study when they were recruited to ORACLE. We will trace
both mother and child through the Office of National Sta-
tistics (ONS) and will be informed of the mother or
child's death since discharge from hospital to date. We
will then send an invitation letter to the address obtained
for the woman using the NHS Tracing Service (NSTS). If
no response is obtained the child's GP will be contacted to
check contact details and ascertain if there is a reason e.g.
child is currently in care or non-English speaker etc. Trans-
lations of all study materials will be available should they
be required and an inexpensive pen will be included with
the invitation and information leaflets.
Once we have established contact with the woman and
child we will make every effort to maintain this by the use
of birthday cards and newsletters (to maintain regular
contact) and change of address cards (to facilitate tracking
of address changes). We will receive listings from ONS
quarterly throughout the study so we are aware of embar-
kations and deaths are notified immediately. We may
consider giving maternity units and GP's surgeries posters
and information leaflets so women can contact us
directly. We confirm current address using NSTS prior to
contact when the child is 7 years old. The Information
Leaflet is sent to the parents, and two weeks later a ques-
tionnaire. Should no response be obtained this is fol-
lowed by two letters, a fortnight apart, to the GP to
ascertain whether we have the correct address and contact
information. Following this confirmation a reminder let-
ter is sent to the parent's/carers the week of the child's 7th
birthday including a ~5 voucher which is sent recorded
delivery. Should no response be forthcoming the last
reminder is done 3 weeks after that and involves either let-
ter or telephone contact, where a phone number is availa-
ble.
A consent form for educational outcomes (KS1) is sent to
parents in England only. KS1 data is to be collected from
either schools or Local Education Authority (LEA).
A thank you card will be sent to parents once the question-
naire has been completed and it is planned to send the
results of the follow-up to parents, should they request
them, in 2008.
Safety
This study is not actively treating women – it is the follow
up of the children. However, clinical care is different for
the two groups. It is recommended that women with pre-
term rupture of the membranes receive erythromycin and
women with spontaneous preterm labour are not pre-
scribed antibiotic therapy.
A Data Monitoring Committee (DMC) has been estab-
lished and will meet annually to consider interim analy-
ses. The Committee will determine if additional interim
analyses of trial data should be undertaken. It will con-
sider the data from interim analyses, unblinded if consid-
ered appropriate, plus any additional safety issues and
relevant information from other sources. In the light of
this, and ensuring that ethical considerations are of prime
importance, to report (following each DMEC meeting) to
the Trial Steering Committee (TSC) and to recommend on
the continuation of the study. The DMC will consider any
requests for release of interim trial data and to recom-
mend to the TSC on the availability of this and in the
event of further funding being required, to provide to the
TSC and MRC appropriate information and advice on the
data gathered to date that will not jeopardise the integrity
of the study.
The DMC membership is Professor Diane Elbourne,
Chair, Professor of Health Care Evaluation, London
School of Hygiene and Tropical Medicine; Ms Helena
McNally, ECMO Trial, NPEU; Professor Martin Whittle,
Clinical Co-Director, National Collaborating Centre for
Women and Children's Health, London.
Publication and dissemination of results
The results will be published in scientific journals. A writ-
ing committee will consist of all applicants with Sara
Kenyon taking the lead on writing the paper. To safeguard
the scientific integrity of the study, data should not be pre-
sented in public or submitted for publication without the
consent from the Trial Steering Committee (see organisa-
tion below)
Organisation and Governance
The protocol and all subsequent amendments received
approval from West Midlands Multicentre Research Ethics
Committee Date of approval April 2002 Reference
number MREC/03/7/14. The study will be sponsored by
University Hospitals Leicester. The study will be run
according to the MRC Good Clinical Practice Guidelines
and UK Data Protection requirements. The study will be
monitored on a day-to-day basis by the Study Office based
at the University of Leicester with the Project Management
Group which consists of all the applicants.
The study will be overseen by a Trial Steering Committee
(TSC) with the following terms of reference: to monitor
and supervise the progress of the trial MRC ORACLE Chil-
dren Study towards its interim and overall objectives; to
review at regular intervals relevant information from
other sources (eg, other related trials); to consider the rec-
ommendations of the DMC; in the light of these to inform
the Council and relevant Research Boards on the progressBMC Pregnancy and Childbirth 2008, 8:14 http://www.biomedcentral.com/1471-2393/8/14
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Tracing and contact mechanisms Figure 1
Tracing and contact mechanisms.BMC Pregnancy and Childbirth 2008, 8:14 http://www.biomedcentral.com/1471-2393/8/14
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Child in 7th year Figure 2
Child in 7th year.BMC Pregnancy and Childbirth 2008, 8:14 http://www.biomedcentral.com/1471-2393/8/14
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KS1 data extraction Figure 3
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of the trial; to advise Council on publicity and the presen-
tation of all aspects of the trial.
Membership
Richard Lilford, Chair, Professor of Clinical Epidemiol-
ogy, University of Birmingham; Dr Catherine Elliott, MRC
Head Office; Professor Richard Cooke, Consultant
Neonatologist, Liverpool Women's Hospital; Mr Chris
Whetton, Assistant Director, National Foundation for
Educational Research; Gill Gyte National Childbirth
Trust; Dr Phillippa Russell, Director, National Council for
Disabled Children; Julie Cahill, School Improvement
Advisor, London.
Discussion
The ORACLE Children Study will provide important
information about the health, development and educa-
tional attainment of children at 7 years of age whose
mothers were exposed to peripartum antibiotics. This
information will be important to both parents and clini-
cians when faced with either preterm ruptured mem-
branes or threatened spontaneous preterm labour.
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